UnknownPhase 2NCT04961788

Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shanghai Zhongshan Hospital
Principal Investigator
Jian Zhou, MD & PhD
Shanghai Zhongshan Hospital
Intervention
Gemox combimed PD1 antibody(drug)
Enrollment
30 enrolled
Eligibility
18-75 years · All sexes
Timeline
20212022

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04961788 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma

← Back to all trials